Related Experiment Video
Updated: Jun 3, 2026

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy
Published on: January 25, 2019
Intravitreal anti-VEGF drugs as adjuvant therapy in diabetic retinopathy surgery
Javier A Montero1, José María Ruiz-Moreno, Maria E Correa
1Retina Section, Pio del Rio Hortega University Hospital, Valladolid, Spain. javmonmor@hotmail.com
Abstract:
The use of intravitreal anti vascular endothelial growth factor (anti-VEGF) drugs such as pegaptanib, ranibizumab and bevacizumab has been widely reported to treat complications such as macular edema and rubeosis. During the past few years they have also been used as an adjuvant therapy to reduce intraocular bleeding during vitrectomy in eyes with proliferative diabetic retinopathy as well as to reduce the occurrence of vitreous haemorrhages in vitrectomized eyes and facilitate glaucoma surgery. In this paper we review the use of anti VEGF drugs in the surgical management of diabetic retinopathy related complications.
Related Concept Videos
Diabetic Retinopathy
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment